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Abstract
Introduction: Recently, arrays have become available that allow the simultaneous analysis of several anti-citrullinated
protein antibody (ACPA) reactivities using distinct citrullinated peptides. Such assays are designed for exploratory studies.
The interpretation of positive antibody reactivities can best be made if the diagnostic and prognostic value of a multiplex
array in an early arthritis setting is known and if the multiplex-positive patients who are negative according to three
commonly used commercial ACPA assays are characterized.
Methods: Using Thermo Scientific’s ImmunoCap ISAC (Immuno Solid-phase Allergen Chip) system, a multiplexed array
that determines reactivities to 11 citrullinated peptides, we analysed serum/plasma of 195 healthy controls and 1282 early
arthritis patients from two independent cohorts: the Leiden Early Arthritis Clinic (n = 1013) and the IMPROVED (n = 269)
cohort. Findings were compared with results primarily of the anti-citrullinated cyclic peptide 2 (anti-CCP-2) assay but also
with anti- CCP-3 and anti-mutated citrullinated vimentin (anti-MCV) assays. The associations between ACPA reactivities
and patient characteristics, risk factors (shared epitope, smoking) and disease outcomes (progression of undifferentiated
arthritis to rheumatoid arthritis (RA) and severity of joint destruction) were assessed.
Results: Thirty-one percent of anti-CCP-2-negative RA patients displayed reactivity toward citrullinated peptides in the
multiplex assay. These patients had a positive signal toward a more restricted peptide repertoire than anti-CCP-2-positive
RA patients (median of 1 versus 5). Within anti-CCP-2-negative patients, ACPA reactivity as detected by multiplex array
was not significantly associated with known risk factors or clinical or prognostic parameters. The frequency of sera from
anti-CCP-2-negative RA patients who were positive for the multiplexed peptides was comparable to the frequency in
non-RA arthritic patients (27 %).
Conclusions: Additive citrulline peptide reactivities detected by the current multiplex system did not reach significant
power to be RA-specific. The presence of residual citrulline reactivities detected by this multiplex system in arthritis
patients who are negative in commercial ACPA assays needs to be interpreted with caution.
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Introduction
Rheumatoid arthritis (RA) is a systemic inflammatory dis-
ease characterized by extensive inflammation of synovial
joints [1]. Patients with RA frequently present with auto-
antibodies, of which the anti-citrullinated protein antibodies
(ACPAs) are of particular interest. These autoantibodies are
highly specific for RA and specifically target proteins that
have undergone a post-translational modification that con-
verts arginine to citrulline residues. ACPAs can be used to
predict the development of RA as these autoantibodies can
be detected up to 10 years prior to disease onset [2, 3].
Furthermore, ACPAs can subdivide patients with RA in
distinct disease subsets. These subsets differ substantially in
clinical outcome and with regard to underlying genetic and
environmental risk factors [4–6].
Several commercial tests are available that use specific
citrullinated antigens to determine ACPA positivity. The
most widely used tests are anti-citrullinated cyclic peptide 2
(anti-CCP-2), anti-CCP-3 and anti-mutated citrullinated
vimentin (anti-MCV) [7, 8]. Anti-CCP-2 has been used in
most studies and has long been the standard test to deter-
mine reactivity to citrullinated peptides, although the se-
quence identity has not been disclosed [9]. It has been
postulated that because commercial anti-CCP-tests employ
peptide sequences that are most likely not derived from hu-
man proteins, these tests do not detect part of the
citrullinated-peptide reactivities [10]. Therefore, arrays have
been developed to do exploratory studies on a large num-
ber of peptides. This could be important to enhance under-
standing of disease as well as identify antibody systems that
are predictive of disease characteristics which can occur in
a number of different diseases such as exocrine gland dys-
function, which is associated with anti-Sjögren’s syndrome-
related antigen A (anti-SSA) antibodies.
Recently, arrays have become available that can deter-
mine citrullinated peptide reactivities toward a wide
variety of natural citrullinated antigens in a relatively
high-throughput setting [10, 11]. Intriguingly, these arrays
showed the presence of reactivities against citrullinated
peptides within anti-CCP-2-negative RA patients. This
raised the question of what a positive signal in such an
array means, and to guide subsequent exploratory studies,
we determined whether a positive signal in a multiplex
assay has an additive value over commercial assays deter-
mining the presence of ACPA and whether these patients
share the characteristics of RA patients positive in com-
mercial ACPA assays.
We aimed to perform a detailed characterization of the
value of multiplex ACPA testing in an early arthritis
setting by studying the characteristics of anti-CCP-2-nega-
tive patients who are positive or negative for additional
citrulline reactivities. We studied clinical parameters and
the presence of genetic and environmental risk factors by
using a previously validated multiplex chip-based array,
the ImmunoCAP ISAC (Immuno Solid-phase Alergen
Chip) system [11–14]. Using this array, we measured
reactivity against 11 different citrullinated peptides derived
from fillagrin, type II collagen, alpha-enolase, fibrinogen




Citrullinated peptide reactivities were assessed on baseline
plasma samples of arthritis patients (n = 1013) included in
the Leiden Early Arthritis Clinic (EAC). This Dutch cohort
was initiated in 1993 and includes patients with a recent
onset of arthritis (symptom duration of less than 2 years)
from the Leiden area [15, 16]. Definitive diagnoses were
determined after 1 year of follow-up by an experienced
rheumatologist. In the current analysis, 564 patients ful-
filled the American College of Rheumatology (ACR) 1987
criteria for RA and they are called ‘Leiden RA patients’.
Patients not fulfilling the RA criteria, who had no other
definite clinical diagnosis, were classified as undifferenti-
ated/unclassified arthritis (UA) (n = 297). The remaining
149 patients were classified as non-UA/non-RA patients;
135 out of 149 patients were anti-CCP-2-negative and
these presented with a wide variety of diagnoses
(Additional file 1).
We also assessed citrullinated peptide reactivities in base-
line serum samples of 269 patients who were included in
the IMPROVED study and who fulfilled the ACR 1987 cri-
teria for RA at the time of inclusion [17]. The IMPROVED
study (ISRCTN11916566) was a randomized controlled
trial investigating the effect of different treatment regimens
in early arthritis.
Genotyping of the HLA-DRB1 region in order to deter-
mine the number of RA-associated shared epitope (SE)
alleles was available for 500 patients (EAC only) [18].
Within the EAC, radiographs were taken at baseline and at
yearly follow-up visits for 7 years. In total, 2340 sets of
hands and feet radiographs of 463 patients with RA were
scored by using the Sharp-van der Heijde scoring (SHS)
methods by one experienced reader with known time order
(intra-class correlation coefficient of 0.91) [19].
Patient samples were compared with serum samples of
195 healthy controls. These controls lived in the Leiden
area and were matched to the patients for age and gender.
Controls were questioned extensively about the presence
of rheumatic conditions and joint complaints and were
excluded if such complaints were present. The prevalence
of IgM-rheumatoid factor (IgM-RF) and anti-CCP-2 are
comparable to those of the general population.
The study was performed in accordance with the Declar-
ation of Helsinki, and protocols were approved by the Lei-
den University Medical Center ethics committee. Informed
consent was obtained.
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Citrullinated peptide assays
Anti-CCP-2 was measured on the Immunoscan RA Mark
2 (Eurodiagnostica, Arnhem, The Netherlands) with a cut-
off of 25 arbitrary units in all patients. Anti-CCP-3 and
anti-MCV were measured in 454 EAC RA patients by,
respectively, Quanta lite CCP 3.1 IgG/IgA (Inova Diagnos-
tics Inc., San Diego, CA, USA) and Orgentec Diagnostika
GmbH (Mainz, Germany) with a cutoff of 20 arbitrary
units. Cutoffs were set by using the instructions of the
manufacturer. IgM-RF was determined by an enzyme-
linked immunosorbent assay (ELISA)-based system with a
cutoff as specified by the manufacturer in 614 patients
with RA (EAC and IMPROVED cohort).
Antibody responses to citrullinated peptides were
measured with the ImmunoCAP ISAC system (Thermo
Fisher Scientific) that contains 11 different citrullinated
peptides and their arginine counterparts: CCP1, CitC1
(CII355-378cit3), CEP1, Fibα36-50, Fibα621-635, Fibβ36-
52, Fibβ60-74, Fibβ563-583, Fibβ580-600, Vim2-17 and
Vim60-75 as described elsewhere [11–14, 20]. We ex-
cluded 4 % of the tested samples from the analyses as anti-
body responses could not be accurately determined
because of high background signals or unspecific reactivity
toward streptavidin.
For cutoff calculations, the citrulline-specific signal was
used (difference in fluorescence intensity between the
citrullinated peptide and the arginine-containing peptide).
The cutoff was established as the mean plus two times the
standard deviation (SD) of the citrulline-specific signals in
195 healthy control sera. For CitC1 (a peptide derived
from collagen type II), we used the citrulline signal with-
out subtracting the arginine signal as this is a non-linear
peptide and has independent but exclusive reactivities to
the arginine counterpart [21].
For reasons of sample availability, plasma of EAC patients
and serum of IMPROVED patients and healthy controls
were used for the multiplex assay. For several individuals
(n = 59), both serum and plasma was available. Results were
comparable between serum and plasma in 92 % of cases
(data not shown).
Statistical analysis
Linear regression was performed to study the association
between log-transformed median anti-CCP-2 levels and
the number of peptides recognized in the multiplex
array. Differences in anti-CCP-2 levels between groups
were analysed with the Mann-Whitney test.
To determine the association between the risk factors of
HLA-SE, smoking and RA, unconditional logistic regres-
sion analysis was performed to calculate odds ratios (ORs)
and 95 % confidence intervals (CIs). Multiplex-negative
RA patients (either anti-CCP-2-negative or -positive) were
used as the reference category and compared with
multiplex-positive RA patients (again in both categories:
anti-CCP-2-positive or anti-CCP-2-negative). Similarly, the
association between multiplex positivity or anti-CCP-2
positivity and progression to RA was assessed. To study
progression, we used selected patients who are classified as
UA patients at baseline and we assessed the development
of RA in the first year of follow-up by using the ACR 1987
criteria for RA.
To study biological interaction between smoking,
HLA-SE and multiplex positivity in anti-CCP-2-negative
RA patients, logistic regression analysis was performed
as described elsewhere [22]. To analyse the rate of joint
destruction, a multivariate normal regression model for
longitudinal data with log-transformed SHS as response
variable was used as previously described [23]. This
method analyses all repeated measures at once and takes
advantage of the correlation between these measure-
ments. Analyses were adjusted for age, gender and dif-
ferent inclusion periods as proxy for treatment strategy
[15]. Anti-CCP-2-negative RA patients were used as ref-
erence and compared with anti-CCP-2-positive RA pa-
tients. We also used anti-CCP-2-negative multiplex-
negative and anti-CCP-2-negative multiplex-positive RA
patients as a reference and these were compared with,
respectively, anti-CCP-2-negative multiplex-positive and
anti-CCP-2-positive multiplex-positive RA patients. The
beta (β) indicates the relative fold increase in radio-
graphic joint damage per year.
Results
Presence of citrulline reactivities by multiplex assay in
patients with RA
Before embarking on determining the diagnostic value of a
prototype multiplex array in an early arthritis setting, we
wished to validate the assay by comparing the results in the
Leiden population of patients with RA with previously pub-
lished data by using other sets of patients with RA. We
used a multiplex array to measure reactivities against the ar-
ginine and citrulline variants of 11 different antigens. A co-
hort of healthy controls was used to establish the cutoff for
each of the tested antigens. All citrullinated peptides were
recognized by a proportion of patients with RA in the EAC
and the IMPROVED cohort (Fig. 1a). In 8 % of the tested
healthy controls, citrulline reactivities were present and 13
out of 15 multiplex-positive controls recognized a single
citrullinated peptide (Fig. 1b). In patients with RA, citrulline
reactivities were observed in the majority of patients (64 %
in EAC and 75 % in IMPROVED) and positive patients
were generally positive for more than one peptide (79 % in
EAC and 84 % in IMPROVED, Fig. 1c). Notably, the fre-
quency of anti-CCP-2-positive RA patients is higher in the
IMPROVED than in the EAC (65 % versus 51 %) and this
is probably explained by the different inclusion criteria.
We next focused on anti-CCP-2-positive RA patients. The
multiplex chip-based array detected citrullinated peptide
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reactivities in 274 out of 285 (96 %) anti-CCP-2-positive
EAC RA patients (Fig. 2a). Percentages were comparable
in the IMPROVED cohort (169/174, 97 %) and with anti-
MCV- or anti-CCP-3-positive EAC RA patients (241 out
of 273 (88 %) and 234 out of 261 (90 %), respectively). The
number of recognized citrullinated multiplex peptides
associated with median anti-CCP-2 antibody levels (Fig. 2b,
R2 = 0.86, P < 0.0001) as has also been reported for ACPA
fine specificities determined by ELISA [24]. Likewise, the
4 % of anti-CCP-2-positive multiplex-negative RA patients
displayed lower anti-CCP-2 levels (Fig. 2c, P = 0.009).
These data show that nearly all anti-CCP/MCV-positive
Fig. 1 Citrulline reactivities in patients with RA and healthy controls. a Plot depicts the frequency of positive RA patients in the EAC (n = 564, in black) or
the IMPROVED (n = 269, in white) cohort and healthy controls (n = 195, in grey) for the different tested citrullinated peptides. b Percentage of healthy
controls plotted against the number of citrulline reactivities. c Percentage of patients with RA (EAC in black and IMPROVED in white) plotted against the
number of citrulline reactivities. CCP cyclic citrullinated peptide, EAC Leiden Early Arthritis Clinic, IMPROVED, RA rheumatoid arthritis
Fig. 2 Multiplex positivity correlates with anti-CCP-2 levels. a Percentage of anti-CCP-2-positive RA patients (n = 285) in the EAC that are positive
or negative in the multiplex array. b Median anti-CCP-2 levels plotted against the number of recognized peptides. A linear regression was used to
determine the degree of correlation. c Anti-CCP-2 levels in multiplex-negative (n = 11) and -positive (n = 274) RA patients. Each dot represents an
EAC patient. Median anti-CCP-2 levels were compared by using the Mann-Whitney test. CCP cyclic citrullinated peptide, EAC Leiden Early Arthritis
Clinic, RA rheumatoid arthritis
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RA patients are positive in the multiplex array. The small
multiplex-negative subgroup represents patients with
lower anti-CCP-2 levels.
Most importantly, the test characteristics described
above are comparable to previously published data, indi-
cating that the multiplex array reproducibly detected
reactivities against commonly used citrullinated peptide
tests in patients with RA.
Multiplex-positive anti-CCP-2-negative RA patients
Recent reports using multiplex platforms with citrulli-
nated peptides also showed positive response in anti-
CCP-2-negative RA patients [10, 11, 24]. To determine
whether this could also be found in the Leiden RA
population, we next analysed the multiplex array re-
activity in the anti-CCP-2-negative RA population. In
the EAC, 31 % (86/279) of the anti-CCP-2-negative
RA patients tested positive in the multiplex assay ver-
sus 34 % (31/91) in the IMPROVED cohort (Fig. 3a).
Similar percentages were found in anti-CCP-3-negative
(29 %, 56/193) or anti-MCV-negative (27 %, 49/181)
RA patient populations. These findings are also compar-
able to previously reported observations using similar
assays in other sets of patients. As anti-CCP-2-positive
multiplex-negative RA patients are rare (4 %), it was not
possible to perform detailed analyses in this population
with sufficient power.
Diagnostic value of the multiplex array in an early
arthritis setting
The finding that a substantial proportion of ACPA-negative
RA patients, as determined by three commercial assays,
shows reactivity in the multiplex assay is intriguing and
prompted us to determine whether this assay has an additive
value over “conventional” ACPA testing in an “early arthritis
setting”. We next analysed multiplex positivity in EAC pa-
tients with a form of arthritis other than UA or RA (so-
called non-RA, n = 149). Thirty percent (45/149) of non-RA
patients were multiplex-positive. In anti-CCP-2-negative
(135/149) non-RA patients, 27 % (37/135) were multiplex-
positive, without a predilection for a particular diagnosis
(Fig. 3b). Similar findings were made when the anti-CCP-3
and anti-MCV assays were used to determine the presence
of ACPAs.
The findings described above were reflected in the
sensitivity and the specificity (in relation to the original
Fig. 3 Multiplex positivity in anti-CCP-2-negative RA patients is not RA-specific. a Percentage of anti-CCP-2-negative RA patients (n = 279) in the EAC
who are positive (n = 86) or negative (n = 193) in the multiplex array. b Pie diagram summarizes the percentage of multiplex-positive (n = 37, grey)
and -negative (n = 98, white) anti-CCP-2-negative non-RA/UA patients (n = 135). Bar diagram plots the number of patients who are multiplex-positive
and -negative with different diagnoses. c-d ACR 1987 criteria were used to calculate the sensitivity and specificity for RA of the anti-CCP-2 test (c) and
of the multiplex array (d) by comparing patients who fulfilled the ACR 1987 criteria with patients who did not (UA patients or patients with a different
form of arthritis). ACR American College of Rheumatology, CCP cyclic citrullinated peptide, EAC Leiden Early Arthritis Clinic, LR likelihood ratio, MCTD
mixed connective-tissue disease, RA rheumatoid arthritis, UA undifferentiated arthritis
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ACR 1987 criteria) of the multiplex assay (63.8 % and
63.7 %) in comparison with the anti-CCP-2 ELISA (51 %
and 87 %). To calculate the sensitivity and specificity, all
446 patients in the EAC without RA were taken into
account. These patients had either UA or another form
of arthritis. The positive likelihood ratio (LR+) for the
multiplex is lower (1.76 versus 4.02 for anti-CCP-2),
whereas the LR− is similar (0.57) (Fig. 3c, d). These ana-
lyses were performed by using the ACR 1987 criteria for
RA since the European League Against Rheumatism/
ACR 2010 criteria include anti-CCP-2 status, thereby
introducing potential circular reasoning.
The diagnosis of non-RA patients was initially assessed
after 1 year by an experienced rheumatologist. To rule
out the possibility that the multiplex-positive non-RA
patients were misdiagnosed or that they developed RA
later in time, we re-assessed their diagnosis, radiographs
and medication use at their last visit. Two non-RA
patients were now diagnosed with RA. When we took
these findings into consideration and assumed that these
two patients were initially misdiagnosed, the sensitivity
of the multiplex assay increased from 63.7 % to 64.1 %.
All analyses described above have been performed by
using the same cutoff (mean + 2 × SD of the citrulline-
specific signal in healthy controls). However, using several
different cutoffs did not change the outcome or conclusions
of the studies (data not shown).
Together these data illustrate that a large subset of anti-
CCP/MCV-negative arthritis patients is positive in the
multiplex array. However, the multiplex has a low RA
specificity.
Characteristics of anti-CCP-2-negative RA patients positive
or negative for citrullinated peptide reactivities
As the multiplex assay was designed to identify antibodies
and antibody patterns to formulate new hypotheses regard-
ing of value for understanding aetiology, pathogenesis, prog-
nosis and prediction, we wished to investigate whether the
multiplex assay could be useful to stratify anti-CCP-2-nega-
tive RA patients into different subsets using other outcome
parameters. There were no statistical differences in baseline
characteristics between multiplex-negative and -positive
EAC patients, although female anti-CCP-2-negative patients
were more often multiplex-positive (P= 0.04, Additional file
2). Given the large number of comparisons performed, this
is not significant.
Citrullinated-peptide repertoire recognized by anti-CCP-2-
negative, multiplex-positive RA patients
We next analysed in more detail the reactivity patterns of
sera from multiplex-positive anti-CCP-2-negative sera.
Multiplex-positive anti-CCP-2-negative subjects (either RA
or healthy or non-RA) recognized mostly one peptide
(median of 1 in anti-CCP-2-negative versus 5 in anti-CCP-
2-positive) as previously reported [11].
Eight-five percent of the anti-CCP-2-negative sera in
the EAC that are positive for a single peptide are
positive for Fibα36-50 or Fibβ563-583 (122/143)
(Additional file 3). As the fraction of anti-CCP-2-
negative multiplex-positive patients relies largely on
these two peptide reactivities, we studied these in
more detail (Additional file 4). Anti-CCP-2-negative
patients with reactivities toward Fibβ563-583 were
mostly positive just above the cutoff (Additional file
4). This was not unique for this peptide as this was
also observed for other citrullinated peptide reactiv-
ities. Fibα36-50 was the exception as a substantial
number of anti-CCP-2-negative RA patients tested
clearly positive against this peptide (Additional file 4),
although recognition of this peptide was not RA-
specific. After removal of these two peptides from the
analysis, 15 % of anti-CCP-2-negative RA patients
were multiplex-positive versus 5 % of non-RA pa-
tients. This also led to a decreased sensitivity (54 %)
but an increased specificity (81 %) of the multiplex
assay.
Risk factors and anti-CCP-2-negative RA patients positive
or negative for citrullinated peptide reactivities
Previously, it was shown that the presence of anti-CCP-2
antibodies associates with HLA-SE alleles and smoking [5,
6]. Indeed, we found an increased frequency of HLA-SE
alleles (43 % versus 79 %, OR = 4.82, P < 0.001) and smok-
ing (22 % versus 32 %, OR = 1.57, P = 0.004) in anti-CCP-
2-positive versus -negative RA patients (Table 1). In con-
trast, in the anti-CCP-2-negative subset, we found no dif-
ference in the frequency of HLA-SE alleles (46 % versus
39 %, OR = 0.74, P = 0.28) and smokers (21 % versus 21 %,
OR = 0.90, P = 0.71, Table 1) between multiplex-negative
and -positive RA patients. We did observe an increased
frequency of HLA-SE alleles and smoking in multiplex-
positive anti-CCP-2-positive RA patients compared with
multiplex-positive anti-CCP-2-negative RA patients (79 %
versus 38 % and 29 % versus 21 %, Table 1).
We also studied IgM-RF, which co-occurs with anti-
CCP-2 (29 % in anti-CCP-2-negative and 91 % in anti-
CCP-2-positive RA, P < 0.001), but again no increased
frequency of IgM-RF was found in the subgroup of anti-
CCP-2-negative multiplex-positive RA patients compared
with multiplex-negative patients (25 % versus 33 %) [25].
These findings were replicated with anti-MCV- and anti-
CCP-3 (data not shown). Together, these data show that
anti-CCP/MCV-negative multiplex-positive RA patients
cannot be distinguished from anti-CCP/MCV-negative
multiplex-negative RA patients by using the read-outs
described.
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Correlation of multiplex array positivity with clinical
outcome in anti-CCP-2-negative patients
Next, we wished to study whether the multiplex assay aids
in the prognosis of clinical outcome. In the EAC cohort, it
is known that anti-CCP-2-positive UA patients have an
increased risk to progress toward RA in the first year of
follow-up as compared with anti-CCP-2-negative UA
patients (30 % versus 68 %, Fig. 4a). Within the anti-CCP-
2-negative subset, positivity in the multiplex array was not
associated with progression (30 % in multiplex-negative
versus 30 % in multiplex-positive). Accordingly, multiplex-
positive UA patients who are anti-CCP-2-positive have a
higher risk to progress than multiplex-positive anti-CCP-2-
negative UA patients (71 % versus 30 %, Fig. 4a).
Likewise, with regard to joint damage, anti-CCP-2-
positive RA patients had 11 % more joint destruction per
year (β = 1.11, CI = 1.08-1.14, P < 0.001), which accumu-
lated over 7 years of follow-up (Fig. 4b). There was no sig-
nificant association with joint destruction over time when
multiplex-negative anti-CCP-2-negative and multiplex-
positive anti-CCP-2-negative patients were compared (β =
1.02, CI = 0.99-1.06, P = 0.15, Fig. 4c). In line with this
observation, within the multiplex-positive RA subset, anti-
CCP-2-positive patients have more joint destruction over
time than anti-CCP-2-negative RA patients (β = 1.09, CI =
1.05-1.13, P < 0.001, Fig. 4d). Together, these data show no
added clinical value of the multiplex array, using 11 citrul-
linated peptides, over the existing anti-CCP-2 test with re-
gard to clinical phenotype or outcome of disease.
Discussion
In this report, we extensively analysed the first multiplex
array, consisting of 11 different citrullinated peptides for
detection of ACPAs, in an early arthritis setting. The multi-
plex array can identify most RA patients who are positive
in the conventional ACPA tests. A large subgroup of RA
patients who are negative in commercial ACPA tests,
including anti-CCP-2/3 and anti-MCV, are positive for one
or more reactivities in the multiplex array. These reactiv-
ities have the potential to discover new autoantibody
systems or lead to understanding of auto-immune reactions
in RA. However, on a group level, these “additional” identi-
fied reactivities do not contribute additional clinical infor-
mation. Furthermore, patients who are multiplex-positive
but anti- CCP-2-negative differ from anti- CCP-2-positive
RA patients with regard to ACPA risk factors (HLA-SE and
smoking), the presence of IgM-RF and clinical parameters
(UA to RA progression and joint destruction), but do not
differ from anti-CCP-2-negative patients.
The fact that the current analysis made use of a single
platform is a limitation. Nonetheless, the findings are in
line with results obtained by other platforms [10, 24,
26]. Wagner et al. performed the most detailed analysis
so far by using a bead-based array that included a larger
number of citrullinated antigen (n = 16) in a small co-
hort of patients with RA, disease controls and healthy
controls (n = 78) [10]. In this cohort, array positivity
(defined as positive for more than one reactivity) was
poorly RA-specific (50 %). Replication in a larger cohort
of patients with RA and healthy controls without dis-
ease controls resulted in a high specificity of 95 %, sup-
porting the importance of disease controls for multiplex
validation studies. When array positivity was defined as
positive for more than two reactivities, the specificity in-
creased to 85 %. Likewise, when we determined specifi-
city as positive for more than one epitope, the
specificity also increased (from 54 % to 85 %). In our
study, this is explained mostly by the exclusion of pa-
tients who are single-positive for Fibα36-50 or Fibβ563-
583 that had poor discriminative capacity. Wagner et al.
showed that eight out of the 16 antigens that they tested
had no discriminative capacity, confirming the import-
ance of a critical selection of applied antigens [10].
Wagner et al. found that at least 10 % of anti-CCP-2-
negative RA patients were ACPA-positive. In this analysis,
ACPA-positive was much more stringently defined
(positive for more than two antigen reactivities with posi-
tive defined as mean + 3x the SD of the signal in healthy
controls). Consistent with our findings, they also described
that anti-CCP-2-negative RA patients who are positive for
citrulline reactivities recognize a more restricted peptide
repertoire [10]. Likewise, this observation was also con-
firmed in another study describing a surface plasmon
resonance-based multiplex platform [24].
Table 1 Association of risk factors of HLA-SE and smoking with
multiplex positivity in anti-CCP-2-negative RA patients
Shared epitope
No, n (%) Yes, n (%) OR (95 % CI) P value
CCP-2− 140 (57) 107 (43) Reference
CCP-2+ 54 (21) 199 (79) 4.82 (3.26-7.14) <0.001
CCP-2−Multiplex− 93 (55) 78 (46) Reference
CCP-2−Multiplex+ 47 (60) 29 (39) 0.74 (0.42-1.28) 0.28
CCP-2−Multiplex+ 47 (62) 29 (38) Reference
CCP-2+Multiplex+ 51 (21) 192 (79) 6.10 (3.50-10.64) <0.001
Ever smoker
No, n (%) Yes, n (%) OR (95 % CI) P value
CCP-2− 274 (78) 78 (22) Reference
CCP-2+ 301 (69) 138 (31) 1.61 (1.17-2.22) 0.004
CCP-2−Multiplex− 183 (79) 54 (21) Reference
CCP-2−Multiplex+ 90 (79) 24 (21) 0.90 (0.53-1.56) 0.71
CCP-2−Multiplex+ 90 (79) 24 (21) Reference
CCP-2+Multiplex+ 281 (71) 125 (29) 1.67 (1.01-2.74) 0.004
Statistical comparison of the frequency of smokers and HLA-SE alleles in
anti-CCP-2-positive versus anti-CCP-2-negative RA patients and within
multiplex-positive RA patients
CCP cyclic citrullinated peptide, RA rheumatoid arthritis, OR odds ratio, CI
confidence interval
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Multiplex assays are designed to investigate the pres-
ence of antibodies to a large number of targets in a
high-throughput manner and with very small amounts of
samples. The assay contains a large number of different
peptides, which are derived from native proteins. It is not
clear, however, whether antibodies to the peptides selected
in the array in fact crossreact to native citrullinated proteins
in vivo. It has been shown that antibodies to citrullinated
type II collagen both bind joints in vivo and induce arthritis
in mice, but the included peptide contains two citrullines
that block many antibodies reactive with single citrullines
present on type II collagen in cartilage [26, 27]. Thus, it is
not clear whether any of the selected peptides attract anti-
bodies that have functional relevance in vivo. On the other
hand, this can also be said regarding the CCP-2 test since
in this case the sequence is not publically known and there-
fore no arginine control can be used. Possibly the test con-
tains several peptides that have been selected to give the
highest specificity for RA. Thus, neither of the used tests
gives any information on possible pathogenic or regulatory
influence of the respective antibody reactivities.
In this study, we have focused on the clinical relevance
of citrulline reactivities in anti-CCP-2-negative RA
patients. To the best of our knowledge, only one other
report has focused on the clinical relevance of citrulline
reactivities in anti-CCP-2-negative patients. Pratt et al.
studied the predictive value of reactivity toward citrulli-
nated antigens in an ELISA platform with regard to UA
to RA progression and found that none of the tested
reactivities was as good as anti-CCP-2 in predicting pro-
gression. In line with our observations, reactivities to a
set of citrullinated peptides in anti-CCP-2-negative UA
patients were not associated with disease progression
[28]. Although our findings are in line with results from
other platforms, future work should focus on comparing
citrulline reactivities in independent cohorts of anti-
CCP-2-negative RA patients side by side on different
platforms. To improve multiplex platforms, this work
Fig. 4 Multiplex positivity in anti-CCP-2-negative RA patients does not correlate with clinical outcome. a Scheme depicts the number of patients
whose UA was diagnosed at baseline. Patients were followed for 1 year to study their progression toward RA. b Median SHS during 7 years of
follow-up in anti-CCP-2-negative (n = 1010) and -positive (n = 1330) RA patients. c Median SHS during 7 years of follow-up in anti-CCP-2 negative
RA patients who are multiplex-negative (n = 729) or -positive (n = 281). d Median SHS during 7 years of follow-up in multiplex-positive RA patients
who are anti-CCP-2-negative (n = 281) or -positive (n = 1282). CCP cyclic citrullinated peptide, CI confidence interval, N number of radiographs, OR
odds ratio, RA rheumatoid arthritis, SHS Sharp-van der Heijde score, UA undifferentiated arthritis
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should be directed toward identifying those citrullinated
peptides that have an additive value and are specific for
RA or a specific phenotypical aspect such as the anti-SSA
antibodies. Most importantly, such specified clinical charac-
teristics should be linked with functional knowledge of the
detected antibodies. These platforms need to include more
relevant peptides and these platforms should be validated
by using large cohorts of healthy controls, patients with RA
and disease controls. In this regard, it would be important
to compare the specificity of different peptides in multiple
conformations (e.g., linear and cyclic). Future studies will
also be useful to analyse the relationship of each reactivity
with risk factors and prognosis and to investigate the func-
tional role of these autoantibody specificities in the disease
process. This could facilitate the incorporation of the most
meaningful reactivities in future assays.
Our data indicate that the positive signals found in
anti-CCP-2-negative sera using the current multiplex
system should be interpreted with caution. The detected
signals are dependent on the particular assays of pep-
tides bound to solidphase, known to twist the conform-
ation and increase variability and false-positive signals as
compared with assaying protein-protein interactions. In
addition, for most of the positive signals for detection of
citrullinated peptides, the signal is just above the cutoff.
False-positive signals may therefore contribute to the ob-
servation that citrulline reactivities in anti-CCP/MCV-
negative RA patients are not associated with any of the
known risk factors for ACPA-positive disease. Another
limitation is that the peptide composition of the array is
limited and the truly relevant citrullinated peptides or
proteins are not present. This is especially relevant since
the number of non-fibrinogen peptide-positive, anti-
CCP-2-negative, multiplex-positive patients is low, mak-
ing it impossible to analyse these reactivities. In fact, an
increasing number of citrullinated peptides, not used in
the present array, are reported to have potential patho-
genic properties in the development of arthritis [27, 29].
Conclusions
Our data indicate that residual reactivities to a wide
range of citrullinated joint antigens as measured in
the current multiplex system are unable to subdivide
anti-CCP-2-negative RA patients into clinically dif-
ferent patient subsets. Nonetheless, it is clear that
anti-CCP-2-negative RA patients are clinically hetero-
geneous and there is a need for biomarkers for dis-
ease phenotypes within diseases like RA but also
across different diseases. This would require different
studies in patient cohorts with detailed phenotypical
characteristics which are selected in non-biased ways
[30]. An improved multiplex assay could potentially
accomplish this.
Additional files
Additional file 1: Diagnosis of anti-CCP-2-negative non-RA patients.
Diagnoses of anti-CCP-2-negative non-RA patients (n = 135) as assessed
by an experienced rheumatologist after 1 year of follow-up stratified for
multiplex positivity. CCP cyclic citrullinated peptide, RA rheumatoid
arthritis. (PDF 14 kb)
Additional file 2: Baseline characteristics of anti-CCP-2-negative RA
patients. Baseline characteristics of anti-CCP-2-negative RA patients
(n = 279) that are multiplex-negative or -positive. CCP cyclic citrullinated
peptide, RA rheumatoid arthritis. (PDF 40 kb)
Additional file 3: Peptides recognized by anti-CCP-2-negative EAC
patients. Peptides recognized by anti-CCP-2-negative EAC patients who are
positive in the multiplex assay for a single epitope (n = 143). CCP cyclic
citrullinated peptide, EAC Leiden Early Arthritis Clinic, RA rheumatoid arthritis.
(PDF 24 kb)
Additional file 4: Citrulline reactivities to Fibα36-50 and Fibβ563-583.
a Citrulline reactivities toward Fibβ563-583 in anti-CCP-2-positive (n = 285)
and anti-CCP-2-negative (n = 279) RA patients and non-RA patients (n = 149)
in the EAC. b Citrulline reactivities in arbitrary units (AUs) toward Fibβ563-
583 in anti-CCP-2-positive (n = 174) and anti-CCP-2-negative (n = 92) RA
patients in the IMPROVED cohort. c Citrulline reactivities toward Fibα36-50
in anti-CCP-2-positive (n = 285) and anti-CCP-2-negative (n = 279) RA patients
and non-RA patients (n = 149) in the EAC. d Citrulline reactivities toward
Fibα36-50 in anti-CCP-2-positive (n = 174) and anti-CCP-2-negative (n = 92) RA
patients in the IMPROVED cohort. The dotted line indicates the cutoff.
Reactivities are plotted in AUs. Each dot indicates a unique individual. CCP
cyclic citrullinated peptide, EAC Leiden Early Arthritis Clinic, IMPROVED, RA
rheumatoid arthritis. (PDF 397 kb)
Abbreviations
ACPA: Anti-citrullinated protein antibody; ACR: American College of
Rheumatology; CCP: Cyclic citrullinated peptide; CI: Confidence interval;
EAC: Leiden Early Arthritis Clinic; ELISA: Enzyme-linked immunosorbent
assay; IgM-RF: IgM-rheumatoid factor; IMPROVED: Induction therapy with
Methotrexate and Prednisone in Rheumatoid Or Very Early arthritic
Disease; ISAC: Immuno Solid-phase Alergen Chip; LR: Likelihood ratio;
MCV: Mutated citrullinated vimentin; OR: Odds ratio; RA: Rheumatoid
arthritis; RF: Rheumatoid factor; SD: Standard deviation; SE: Shared
epitope; SHS: Sharp-van der Heijde score; SSA: Sjögren’s syndrome-
related antigen A; UA: Undifferentiated arthritis.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JH was involved in analysis and interpretation of data and wrote the manuscript.
LT, LN and HS were involved in acquisition of data, data analysis and revising the
manuscript. AHM, CA, GS and RH were critically involved in experimental design
and revising the manuscript. TH, RT and DW were involved in experimental
design, experiment supervision and drafting the manuscript. All authors read and
approved the final manuscript.
Acknowledgements
We thank Lars Klareskog at Karolinska Institutet and Johan Ronnelid at
Uppsala University, who had the responsibility for the development of the
present as well as other versions of the ISAC multiplex platform. We
acknowledge Linda Mathson at Thermo Fisher Scientific for her involvement
in the performance of the multiplex assay and Monika Hansson at Karolinska
Institutet for running the multiplex assays and for producing the results. This
work was supported by grants from the IMI EU-funded project BTCure
(contract 115142-2) and the Swedish Strategic Science Foundation (RH). LT
was financially supported by a ZON-MW Vidi grant and a fellowship from
Janssen Biologics (Leiden, The Netherlands).
Author details
1Department of Rheumatology C1-R, Leiden University Medical Center,
Albinusdreef 2, PO Box 9600, Leiden 2300 RC, The Netherlands. 2Laboratory
of Epidermis differentiation and Rheumatoid Autoimmunity, Centre National
van Heemst et al. Arthritis Research & Therapy  (2015) 17:276 Page 9 of 10
de la Recherché Scientifique, Avenue de Grande-Bretagne 330, TSA 40031,
Toulouse 31059Cedex 9, France. 3Department of Medical Biochemistry and
Biophysics, Medical Inflammation Research Unit, Karolinska Institutet,
Stockholm SE-171 77, Sweden.
Received: 9 February 2015 Accepted: 9 September 2015
References
1. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet.
2010;376:1094–108.
2. Rantapää-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H,
et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor
predict the development of rheumatoid arthritis. Arthritis Rheum.
2003;48:2741–9.
3. Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ,
van der Horst-Bruinsma IE, de Koning MH, et al. Specific autoantibodies
precede the symptoms of rheumatoid arthritis: a study of serial
measurements in blood donors. Arthritis Rheum. 2004;50:380–6.
4. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW,
et al. Antibodies to citrullinated proteins and differences in clinical
progression of rheumatoid arthritis. Arthritis Res Ther. 2005;7:R949–58.
5. Huizinga TW, Amos CI, van der Helm-van Mil AH, Chen W, van Gaalen FA,
Jawaheer D, et al. Refining the complex rheumatoid arthritis phenotype
based on specificity of the HLA-DRB1 shared epitope for antibodies to
citrullinated proteins. Arthritis Rheum. 2005;52:3433–8.
6. Klareskog L, Stolt P, Lundberg K, Källberg H, Bengtsson C, Grunewald J, et al.
A new model for an etiology of rheumatoid arthritis: smoking may trigger
HLA-DR (shared epitope)-restricted immune reactions to autoantigens
modified by citrullination. Arthritis Rheum. 2006;54:38–46.
7. van der Linden MP, van der Woude D, Ioan-Facsinay A, Levarht EW,
Stoeken-Rijsbergen G, Huizinga TW, et al. Value of anti-modified citrullinated
vimentin and third-generation anti-cyclic citrullinated peptide compared
with second-generation anti-cyclic citrullinated peptide and rheumatoid
factor in predicting disease outcome in undifferentiated arthritis and
rheumatoid arthritis. Arthritis Rheum. 2009;60:2232–41.
8. Bang H, Egerer K, Gauliard A, Lüthke K, Rudolph PE, Fredenhagen G, et al.
Mutation and citrullination modifies vimentin to a novel autoantigen for
rheumatoid arthritis. Arthritis Rheum. 2007;56:2503–11.
9. van Venrooij WJ, van Beers JJ, Pruijn GJ. Anti-CCP antibodies: the past, the
present and the future. Nat Rev Rheumatol. 2011;7:391–8.
10. Wagner CA, Sokolove J, Lahey LJ, Bengtsson C, Saevarsdottir S, Alfredsson L,
et al. Identification of anticitrullinated protein antibody reactivities in a
subset of anti-CCP-negative rheumatoid arthritis: association with cigarette
smoking and HLA-DRB1 ‘shared epitope’ alleles. Ann Rheum Dis.
2015;74:579–86.
11. Hansson M, Mathsson L, Schlederer T, Israelsson L, Matsson P, Nogueira L, et al.
Validation of a multiplex chip-based assay for the detection of autoantibodies
against citrullinated peptides. Arthritis Res Ther. 2012;14:R201.
12. de Hair MJ, van de Sande MG, Ramwadhdoebe TH, Hansson M, Landewé R,
van der Leij C, et al. Features of the synovium of individuals at risk of
developing rheumatoid arthritis: implications for understanding preclinical
rheumatoid arthritis. Arthritis Rheumatol. 2014;66:513–22.
13. Brink M, Hansson M, Mathsson L, Jakobsson PJ, Holmdahl R, Hallmans G, et al.
Multiplex analyses of antibodies against citrullinated peptides in
individuals prior to development of rheumatoid arthritis. Arthritis
Rheum. 2013;65:899–910.
14. Brink M, Hansson M, Rönnelid J, Klareskog L, Rantapää Dahlqvist S. The
autoantibody repertoire in periodontitis: a role in the induction of
autoimmunity to citrullinated proteins in rheumatoid arthritis? Antibodies
against uncitrullinated peptides seem to occur prior to the antibodies to
the corresponding citrullinated peptides. Ann Rheum Dis. 2014;73, e46.
15. de Rooy DP, van der Linden MP, Knevel R, Huizinga TW, van der Helm-van
Mil AH. Predicting arthritis outcomes–what can be learned from the Leiden
Early Arthritis Clinic? Rheumatology (Oxford). 2011;50:93–100.
16. van Aken J, van Bilsen JH, Allaart CF, Huizinga TW, Breedveld FC, van Aken J,
et al. The Leiden Early Arthritis Clinic. Clin Exp Rheumatol. 2003;21:S100–5.
17. Heimans L, Wevers-de Boer KV, Visser K, Goekoop RJ, van Oosterhout M,
Harbers JB, et al. A two-step treatment strategy trial in patients with early
arthritis aimed at achieving remission: the IMPROVED study. Ann Rheum
Dis. 2014;73:1356–61.
18. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An
approach to understanding the molecular genetics of susceptibility to
rheumatoid arthritis. Arthritis Rheum. 1987;30:1205–13.
19. van der Linden MP, Feitsma AL, le Cessie S, Kern M, Olsson LM,
Raychaudhuri S, et al. Association of a single-nucleotide polymorphism in
CD40 with the rate of joint destruction in rheumatoid arthritis. Arthritis
Rheum. 2009;60:2242–7.
20. Burkhardt H, Sehnert B, Bockermann R, Engström A, Kalden JR, Holmdahl R.
Humoral immune response to citrullinated collagen type II determinants in
early rheumatoid arthritis. Eur J Immunol. 2005;35:1643–52.
21. Dobritzsch D, Lindh I, Uysal H, Nandakumar KS, Burkhardt H, Schneider G, et al.
Crystal structure of an arthritogenic anticollagen immune complex. Arthritis
Rheum. 2011;63:3740–8.
22. Andersson T, Alfredsson L, Källberg H, Zdravkovic S, Ahlbom A. Calculating
measures of biological interaction. Eur J Epidemiol. 2005;20:575–9.
23. Knevel R, Tsonaka R, le Cessie S, van der Linden MP, Huizinga TW, van der
Heijde DM, et al. Comparison of methodologies for analysing the
progression of joint destruction in rheumatoid arthritis. Scand J Rheumatol.
2013;42:182–9.
24. van Beers JJ, Willemze A, Jansen JJ, Engbers GH, Salden M, Raats J, et al.
ACPA fine-specificity profiles in early rheumatoid arthritis patients do not
correlate with clinical features at baseline or with disease progression.
Arthritis Res Ther. 2013;15:R140.
25. Verpoort KN, Cheung K, Ioan-Facsinay A, van der Helm-van Mil AH, de
Vries-Bouwstra JK, Allaart CF, et al. Fine specificity of the anti-citrullinated
protein antibody response is influenced by the shared epitope alleles.
Arthritis Rheum. 2007;56:3949–52.
26. Uysal H, Bockermann R, Nandakumar KS, Sehnert B, Bajtner E, Engström A,
et al. Structure and pathogenicity of antibodies specific for citrullinated
collagen type II in experimental arthritis. J Exp Med. 2009;206:449–62.
27. Haag S, Schneider N, Mason DE, Tuncel J, Andersson IE, Peters EC, et al.
Identification of new citrulline-specific autoantibodies, which bind to
human arthritic cartilage, by mass spectrometric analysis of citrullinated
type II collagen. Arthritis Rheumatol. 2014;66:1440–9.
28. Pratt AG, Charles PJ, Chowdhury M, Wilson G, Venables PJ, Isaacs JD.
Serotyping for an extended anti-citrullinated peptide autoantibody panel
does not add value to CCP2 testing for diagnosing RA in an early
undifferentiated arthritis cohort. Ann Rheum Dis. 2011;70:2056–8.
29. Harre U, Georgess D, Bang H, Bozec A, Axmann R, Ossipova E, et al.
Induction of osteoclastogenesis and bone loss by human autoantibodies
against citrullinated vimentin. J Clin Invest. 2012;122:1791–802.
30. Trouw LA, Mahler M. Closing the serological gap: promising novel
biomarkers for the early diagnosis of rheumatoid arthritis. Autoimmun Rev.
2012;12:318–22.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
van Heemst et al. Arthritis Research & Therapy  (2015) 17:276 Page 10 of 10
